Indian Vaccine Market To Be Worth Rs 252 Billion By 2025: Jitendra Singh

Union Minister Jitendra Singh said on Sunday that the Indian vaccine market is expected to reach Rs 252 billion by 2025, highlighting the country's progress in the pharmaceutical and biotechnology sectors. On Sunday, Singh, who is leading a high-level official Indian delegation from the Ministry of Science and Technology on a 6-day visit to the United Kingdom, paid a visit to the 175-year-old London Science Museum.

He mentioned the government establishing similar science museums in India. The Minister stated that the goal of establishing these museums is to help ordinary citizens, particularly young people, realise their hidden potential and, in some cases, discover inherent abilities that they may be unaware of. It also arouses their curiosity, which may aid in sharpening their scientific temper and inspiring creative innovation.

The Science Museum is a major museum in South Kensington, London, located on Exhibition Road. It was established in 1857. The Minister was shown around the exclusive pavilion that had been set up to trace the history of the Covid pandemic from the first case to the first person to be vaccinated. For people's awareness and education, the history has been recorded in chronological order. The pavilion recognises India's leadership role in the management and prevention of Covid. According to Singh, India is quickly emerging as the world's major bio-economy, and it has grown by leaps and bounds in terms of innovation and technology in recent years.

In just two years, India has developed four indigenous vaccines, he said. The Minister went on to say that the Department of Biotechnology (DBT) in the Ministry of Science and Technology, through "Mission COVID Suraksha," delivered four vaccines, expanded Covaxin manufacturing, and built the infrastructure needed for the smooth development of future vaccines, ensuring that the country is pandemic-ready. Singh stated that the world is becoming more aware of India's exceptional capabilities in preventive healthcare, and that we are currently developing several other vaccines in the series.

Following the success of the first DNA vaccine, the first nasal vaccine was developed, as well as another vaccine related to Human Papillomavirus (HPV) that aids in the prevention of cervical cancer. The Minister underlined that the Indian vaccine market, which has carved out a place for itself at the global level, is expected to reach a valuation of Rs 252 billion by 2025. He also called for extended collaboration in biotech startups and vaccine development between India and the United Kingdom.